Participant no. 2: Paolo Comoglio, University of Torino, Italy
Institution
The Institute for Cancer Research and Treatment (IRCC) in Candiolo near Turin houses large modern laboratories (over 1000 sq. meters) equipped with state-of-the-art technologies, including DNA sequencers, synthesizers, equipment for protein purification, a range of microscopes, work stations and software for real-time image analyses, and automated systems for multiplex in-cell analyses.
Paolo Comoglio and his team at IRCC are involved in the research in two areas of the SFMET project, namely:
- Hypoxia, MET and tumour invasion
- Low molecular weight MET antagonists
Profile of the Group
Paolo Comoglio has a very strong track record of studies in cell signalling and tumour biology. He and his colleagues identified the MET sequences that are critical for signalling, has studied a number of cell surface molecules that interact with MET and has contributed extensively to the characterisation of MET homologues, notably the plexin. The laboratory has also made numerous and critical contributions to the clinico-pathological and genetic analysis of MET in human tumours.
Paolo Michieli is a group leader at IRCC and a lead investigator in the studies on MET antagonists and the role of hypoxia in MET-dependent tumour invasion. Together with Paolo Comoglio he will lead the in vivo studies on hypoxia, MET and tumour invasion.
Sandra Pennachhietti is a senior post-doctoral and the first author of the first paper reporting the effect of hypoxia on MET-expression and activity in cancer cells in culture.
Maria Galluzzo is a post-doctoral fellow working on hypoxia, MET and tumour invasion.
Ada Arnesano is post-doctoral fellow working on hypoxia, MET and tumour invasion.